Skip to main content
SpringerLink
Log in
Book cover

Hybrid PET/CT and SPECT/CT Imaging pp 555–582Cite as

Melanoma

  • Chapter
  • First Online:

  • 1786 Accesses

Abstract

The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database has demonstrated an increase in annual incidence of cutaneous melanoma of 619% and an increase in annual mortality of 165% from 1950 to 2000. In 2004, an estimated 55,000 Americans were newly diagnosed with cutaneous melanoma, and approximately 7,900 died from this disease. Of all cancers in the United States, cutaneous melanoma ranks fifth in incidence among men and seventh among women. It is the most common cancer in women aged 20–29 and the second leading cause of lost productive years.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. New Engl J Med 2004;351:998–1012.

    Article  CAS  PubMed  Google Scholar 

  2. Domingo-Domenech J, Molina R, Castel T, Montagut C, Puig S, Conill C, Martí R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B. Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon – comparison with tyrosinase re-PCR. Oncology 2005;68:341–349.

    Article  CAS  PubMed  Google Scholar 

  3. Garbe C, Leiter, U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase charin reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737–1745.

    Article  CAS  PubMed  Google Scholar 

  4. Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang H-J, Gerami M, Hoon DSB. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003;21:2558–2563.

    Article  CAS  PubMed  Google Scholar 

  5. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.

    CAS  PubMed  Google Scholar 

  6. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C-H, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–983.

    CAS  PubMed  Google Scholar 

  7. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang H-J, for the MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307–1317. Erratum in: N Engl J Med 2006;355:1944.

    Google Scholar 

  8. Alazraki N, Glass EC, Castronovo F, Valdes Olmos RA, Podoloff D. Society of Nuclear Medicine procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness. J Nucl Med 2002;93:1414–1418.

    Google Scholar 

  9. Belhocine TZ, Scott AM, Evan-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006;47:957–967.

    PubMed  Google Scholar 

  10. Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwart A, Gur E, Skornick Y, Schneebaum S. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 2003;44:1413–1420.

    PubMed  Google Scholar 

  11. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237–242.

    Article  CAS  PubMed  Google Scholar 

  12. Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34:242–253.

    Article  PubMed  Google Scholar 

  13. Balch CM, Soong S, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu P-Y, Lyman JH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–3634.

    CAS  PubMed  Google Scholar 

  14. Garbe C, Paul A, Kohler-Späth H. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520–529.

    Article  PubMed  Google Scholar 

  15. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: State of the art 2006. Melanoma Res 2007;17:117–127.

    Article  PubMed  Google Scholar 

  16. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153–167.

    CAS  PubMed  Google Scholar 

  17. Bastiaannet E, Oyen WJG, Meijer S, Hoekstra OS, Wobbes T, Jager PL, Hoekstra HL. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243–249.

    Article  CAS  PubMed  Google Scholar 

  18. Strobel K, Dummer R, Husarik D, Lago MP, Hany MF, Steinert HC. High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244:566–674.

    Article  PubMed  Google Scholar 

  19. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack H-J, Tüting T. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 2006;24:1178–1187.

    Article  PubMed  Google Scholar 

  20. Kato K, Kubota T, Ikeda M, Tadokoro M, Abe S, Nakano S, Nishino M, Kobayashi H, Ishigaki T. Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT. J Nucl Med 2006;47:404–409.

    CAS  PubMed  Google Scholar 

  21. Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: Detection of choroidal melanoma. Br J Ophthalmol 2005;89:1265–1269.

    Article  CAS  PubMed  Google Scholar 

  22. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005;89:1270–1274.

    Article  CAS  PubMed  Google Scholar 

  23. Lane KA, Bilyk JR. Preliminary study of positron emission tomography in the detection and management of orbital malignancy. Ophthal plast Reconstr Surg 2006;22:361–365.

    Article  PubMed  Google Scholar 

  24. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

  25. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations for the Use of FDG(fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.

    Article  PubMed  Google Scholar 

  26. Chiles C, Woodard PK, Gutierrez FR, Link KM. Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 2001;21:439–449.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

    Ronald C. Walker, Laurie B. Jones-Jackson MD, Aaron C. Jessop MD & Dominique Delbeke MD, PhD

Authors
  1. Ronald C. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurie B. Jones-Jackson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aaron C. Jessop MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominique Delbeke MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald C. Walker .

Editor information

Editors and Affiliations

  1. Medical Center, Vanderbilt University, 21st Ave. S. & Garland 1161, Nashville, 37232-2675, U.S.A.

    Dominique Delbeke

  2. Dept. Nuclear Medicine, Rambam Medical Centre, Bat-Galim, Haifa, 35 254, Israel

    Ora Israel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Walker, R.C., Jones-Jackson, L.B., Jessop, A.C., Delbeke, D. (2010). Melanoma. In: Delbeke, D., Israel, O. (eds) Hybrid PET/CT and SPECT/CT Imaging. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92820-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92820-3_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92819-7

  • Online ISBN: 978-0-387-92820-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation